Search
Guanethidine
go.drugbank.com/drugs/DB01170ApprovedWithdrawnAn antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. … It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.
Tafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigational[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. … [A35690] Tafenoquine was further developed collaboratively between GlaxoSmithKline and Medicines for Malaria Venture.[A35677] It was FDA approved on July 20, 2018.[L3770]
Enalaprilat
go.drugbank.com/drugs/DB09477ApprovedInvestigationalUsed in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. … Enalaprilat is poorly orally available and is therefore only available as an intravenous injection for the treatment of hypertension when oral therapy is not possible.
Categories: Antihypertensive Agents Indicated for HypertensionEstradiol valerate
go.drugbank.com/drugs/DB13956ApprovedInvestigationalVet approvedEstradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. … Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women [FDA Label].
Categories: Hormonal Contraceptives for Systemic UseZanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigationalZanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL,[ … In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia.[L39030] This indication is valid in the US, Europe, and Canada.
Hodgkin's Lymphoma
go.drugbank.com/conditions/DBCOND0030382Drugs: Bleomycin · Chlorambucil · Cyclophosphamide · Dacarbazine · Doxorubicin · Gemcitabine +5 moreSynonyms: Hodgkin lymphoma, no International Classification of Diseases for Oncology subtypeUmbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnfrom clinical trials. … While it initially offered a promising therapy for patients experiencing relapsing or refractory disease,[A229363] umbralisib was withdrawn from the market due to safety concerns as the drug was associated
Dorocubicel
go.drugbank.com/drugs/DB19448ApprovedDorocubicel is a preparation of cryopreserved allogeneic umbilical cord-derived hematopoietic stem cells and blood progenitors expanded _ex vivo_ using [UM-171]. … following myeloablative conditioning in adult patients for whom a suitable donor is not available.
Synonyms: Allogeneic human umbilical cord blood expanded with UM-171Cannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalOn June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market. … It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body.
Lotilaner
go.drugbank.com/drugs/DB17992ApprovedInvestigationalVet approved[A260741] On July 25, 2023, lotilaner was approved by the FDA for the treatment of Demodex blepharitis, making it the first and only approved therapeutic for this condition.[L47551] … [L47546] Lotilaner has largely been used for veterinary uses as an antiparasitic agent to treat flea and tick infestations in animals.